Stock Events

Stock Events

Chemomab Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2QV.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap1.88B
Galapagos NV specializes in drug discovery for fibrosis and inflammatory diseases, overlapping with Chemomab's research areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.84B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis and NASH, similar to Chemomab's focus areas.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong portfolio in liver diseases, including fibrosis and NASH, competing with Chemomab's pipeline.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, directly competing with Chemomab.
Agenus
AGEN
Mkt Cap147.45M
Agenus Inc. is involved in immuno-oncology but also explores inflammatory diseases, potentially overlapping with Chemomab's therapeutic areas.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a broad portfolio that includes treatments for inflammatory diseases, indirectly competing with Chemomab in the broader market for anti-inflammatory treatments.

About

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Show more...
CEO
Dr. Adi Mor George Ph.D.
Employees
20
Country
Israel
ISIN
US16385C2035

Listings

F
DE
2QV.F
MU
DE
2QV.MU
STU
DE
2QV.STU
XNAS
US
CMMB

0 Comments

Share your thoughts

FAQ

What is Chemomab Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chemomab Therapeutics stocks are traded under the ticker 2QV.STU.
How many employees does Chemomab Therapeutics have?▼
As of May 06, 2026, the company has 20 employees.
In which sector is Chemomab Therapeutics located?▼
Chemomab Therapeutics operates in the Health & Wellness sector.
When did Chemomab Therapeutics complete a stock split?▼
Chemomab Therapeutics has not had any recent stock splits.
Where is Chemomab Therapeutics headquartered?▼
Chemomab Therapeutics is headquartered in Tel Aviv-Yafo, Israel.